5-Year Follow-up of Children and Mother After Expectant Management Versus Induction of Labor in Low-risk Nulliparous Women at 39 Weeks of Gestation

Обзор

In France, the rate of labor induction has markedly increased in recent years, partly following the ARRIVE trial suggesting short-term benefits of elective induction at 39 weeks in low-risk nulliparous women. This trial is currently being replicated in France (FRENCH-ARRIVE), as maternal characteristics, cesarean rates, and healthcare organization differ from the US. Importantly, no comparative data exist on the mid-term consequences of reducing gestational age at delivery with elective induction of labor-from 41 to 39 weeks-versus usual expectant management on child health and maternal outcomes. Generating such evidence is essential to inform decision making for women reaching 39 weeks of gestation, i.e. the large majority of pregnant women

Подробное описание

In France, the rate of labor induction increased from 20% to 25% of deliveries between 2016 and 2021. This recently dramatic increase also reported in other high income settings, is likely in part related to the publication of the ARRIVE trial (Grobman, NEJM 2018). Before it, induction of labor was usually proposed in case of condition potentially associated to a higher maternal or fetal risk with expectant management compared with an immediate delivery. The ARRIVE trial, a multicenter, randomized, controlled trial suggests a short-term maternal-fetal benefit to systematic induction of labor at 39 weeks of gestation (experimental arm) compared to an expectant management (control arm) in low-risk nulliparous women, with a decreasing trend of adverse perinatal outcome and a significant lower risk of cesarean delivery and maternal hypertensive disorders. Because the generalizability of these results in US outside settings is unknown (as the maternal characteristics, national rate of cesareans and organization and access of care differ in US from an European country including France, this trial is currently replicating in France (FRENCH-ARRIVE trial, PHRCN n° 19-0063) (Sentilhes et al, Lancet 2023; Azria et al, AJOG 2023;)

Regardless of its results (which are not yet available), mid-term follow-up of children born to mothers enrolled in the FRENCH-ARRIVE trial, through the FAMILY-FA project, is crucial:

1 / In absence of comparative data, it remains unknown whether the mid-term child health differs or not according to the late pregnancy management, through the bias of reduction the gestational age at delivery from 41 to 39 weeks for women undergoing an induction of labor, and with possible differences in mode of delivery (all these parameters being associated to mid-term child's health).

2/ For the informed decision making for the women who reach 39 weeks gestation (i.e. the large majority of the pregnant women). Only mid-term data in early childhood after induction of labor for medical reason compared to expectant management are available; but they are obviously flawed by the indication that required the induction of labor (e.g. fetal growth restriction, premature of membranes, etc).

Thus, the first objective of the FAMILY-FA project is to evaluate the mid-term effect of elective induction of labor at 39 weeks of gestation compared with an expectant attitude in low-risk nulliparous women on child neurodevelopment at 5 years.

Similarly, mid-term follow-up of mothers enrolled in the FRENCH-ARRIVE trial with the assessment of obstetrical issues in case of future pregnancy, and maternal mental health, through the FAMILY-FA project, is essential:

1. No comparative data are available on the obstetrical issues including mode of delivery in case of a subsequent pregnancy (the possible reduction of cesarean associated to the elective induction of labor at 39 weeks compared to an expectant management might be associated to a lower rate of cesarean and maternal and neonatal morbidity in a subsequent pregnancy). 2. We have recently shown that induction of labor for medical reason was associated with impairment of maternal mental health in postpartum 3. By assessing the maternal mental health as well as the other components of the life of the women (single or not, subsequent pregnancy or not) concomitantly to assessing the offspring development will allow us to taking into account potential cofounders associated to pediatric neurodevelopment (primary objective of our project). In fact, high quality evidence show that impaired maternal mental health affects intra-familial relationships and may impair the child's development.

Вмешательства

• Поведенческое Questionnaires
  self-administered parental and teacher questionnaires 5 years after the birth of the first child (i.e., 5 years after enrollment in the FRENCH-ARRIVE trial). In addition, for a randomly selected subsample of 12% of participants (n=500), a brief neuropsychological assessment of their child (\~1 hour) will be conducted remotely via videoconference by a trained neuropsychologist

Первичные конечные точки

• pediatric neurodevelopment at 5 years of age [Срок оценки: 5 years old]

Вторичные конечные точки (7)

• Child neurodevelopment [Срок оценки: 5 years old]
• Child cognition [Срок оценки: 5 years old]
• Maternal depression [Срок оценки: Baseline]
• Maternal anxiety [Срок оценки: Baseline]
• Maternal partner relationship satisfaction [Срок оценки: Baseline]
• Maternal precarity [Срок оценки: Baseline]
• Maternal life questionnaire [Срок оценки: Baseline]

Критерии участия

Критерии включения

• Women randomized in the FRENCH-ARRIVE trial (NCT04799912):

• Age ≥ 18 years
• Nulliparous women (i.e. no previous pregnancy beyond 20 weeks)
• With singleton gestation. Twin gestation reduced to singleton, either spontaneously or therapeutically, is not eligible unless the reduction occurred before 14 weeks project gestational age.
• Gestational age at randomization between 37 weeks of gestation 0 day and 38 weeks of gestation 6 days inclusive based on the crown rump length measured at the first trimester ultrasound before 14 weeks of gestation and 0 days, as recommended in France
• Affiliated or beneficiary to a health security system
• Signed informed consent
• Non-opposition from both holders of parental authority to participation in the FAMILY-FA study

Критерии исключения

• Exclusion criteria of the FRENCH-ARRIVE trial:

• Project gestational age at date of first ultrasound is > 14 weeks
• Plan for induction of labor prior to 40 weeks 5 days
• Plan for cesarean delivery or contraindication to labor
• Breech presentation
• Multiple pregnancy
• Signs of labor (regular painful contractions with cervical change)
• Fetal demise or known major fetal anomaly
• Heparin or low-molecular weight heparin during the current pregnancy
• Placenta previa, accreta, vasa previa
• Active vaginal bleeding greater than bloody show
• Ruptured membranes
• Cerclage in current pregnancy
• Known oligohydramnios, defined as Amniotic Fluid Index < 5 or Maximal Vertical Pocket < 2 cm
• Fetal growth restriction, defined as Estimated Fetal Weight < 10th percentile according to local curve
• Known HIV positivity because of modified delivery plan
• Major maternal medical illness associated with increased risk for adverse pregnancy outcome (for example, any diabetes mellitus, lupus, any hypertensive disorder, cardiac disease, renal insufficiency)
• Refusal of blood products
• Participation in another interventional study that may influence management of labor or delivery (labor induction, operative vaginal delivery, cesarean section, shoulder dystocia)
• Delivery planned elsewhere at a non-Network site
• History of myomectomy by laparotomy or laparoscopy
• Previous metroplasty for uterine malformation or Asherman syndrome
• Patient under legal protection
• Poor understanding of the French language
• Moreover: the following postnatal criteria will be also exclusion criteria:

• Major malformations and/or chromosomal aberrations evidenced in the child after birth
• Parents' refusal to participate in the follow-up
• Impossibility to contact the family

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Профилактика

Центры проведения

Франция · 1 центр

• CHU Bordeaux — Bordeaux

Идентификаторы

NCT: NCT07330336 · CHUBX 2024/46

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗